Year-end Sale % OFF 
Abstract
The new oral anticoagulant agents are now available through the PBS for the prevention of thromboembolic complications of atrial fibrillation and the treatment and prevention of venous thrombosis. While more convenient to use than traditional vitamin K antagonists, concerns were initially raised regarding the safety of these agents in a ‘real-life’ setting, particularly given the lack of availability of a validated reversal strategy. Available post-marketing surveillance data to date has been reassuring. This talk will detail current data regarding the ability to assess the anticoagulant effect of the direct thrombin and direct factor Xa inhibitors with both conventional and specific assays. Current recommended strategies for management of bleeding in patients on new oral anticoagulants will be discussed, including the potential clinical implication of the lack of a validated reversal agent. Future specific reversal strategies will also be covered.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
